Serum Institute conducting phase III clinical trial of tuberculosis vaccine: DBT

The BCG vaccine is administered routinely to all newborns as part of the national childhood immunisation programme to prevent tuberculosis (TB), an infection caused by bacteria that mainly affects the lungs. It has beneficial heterologous effects and proven antiviral and immune modulatory properties that protect against infectious diseases through induction of trained innate immunity and heterologous adaptive immunity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3f2KcXN
via IFTTT